Cholinesterase Inhibitors in Parkinson's Disease

D. Aarsland*, C. Ballard

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Cholinergic deficits are marked in Parkinson's disease (PD), and are associated with cognitive impairment and hallucinations. There is emerging evidence suggesting that cholinesterase inhibitors improve cognition, attention, and functioning in PD, although the improvement is modest. Mild and transient worsening of tremor occurs, in addition to nausea and other peripheral cholinergic side effect.

Original languageEnglish
Title of host publicationEncyclopedia of Movement Disorders
PublisherElsevier Inc.
Number of pages4
ISBN (Electronic)9780123741059
ISBN (Print)9780123741011
Publication statusPublished - 2010


  • Cholinesterase inhibitors
  • Cognitive impairment
  • Dementia
  • Donepezil
  • Galantamine
  • Hallucinations
  • Parkinson's disease
  • Rivastigmine


Dive into the research topics of 'Cholinesterase Inhibitors in Parkinson's Disease'. Together they form a unique fingerprint.

Cite this